Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

Yan Li1 Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA

Xiaomin Wang2 Non-Clinical Development and Drug Metabolism and Pharmacokinetics, Celgene Corporation, Summit, NJ, USA

Edward O’Mara1 Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA

Meletios A Dimopoulos3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

Pieter Sonneveld4 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

Katja C Weisel5 Department of Hematology, University Hospital Tübingen, Tübingen, Germany

Jeffrey Matous6 Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, CO, USA

David S Siegel7 Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Jatin J Shah8 Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA

Elisabeth Kueenburg9 Global Clinical R&D, Celgene Corporation, Summit, NJ, USA

Lars Sternas9 Global Clinical R&D, Celgene Corporation, Summit, NJ, USA

Chloe Cavanaugh9 Global Clinical R&D, Celgene Corporation, Summit, NJ, USA

Mohamed Zaki9 Global Clinical R&D, Celgene Corporation, Summit, NJ, USA

Maria Palmisano1 Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA

Simon Zhou1 Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USACorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.